

Resource Summary Report

Generated by [nidm-terms](#) on Aug 11, 2026

Recombinant Anti-GFPT2 antibody [EPR19095]

RRID:AB_2868470

Type: Antibody

Proper Citation

Abcam Cat# ab190966, RRID:AB_2868470

Antibody Information

URL: http://antibodyregistry.org/AB_2868470

Proper Citation: Abcam Cat# ab190966, RRID:AB_2868470

Target Antigen: GFPT2

Host Organism: rabbit

Clonality: recombinant

Comments: Applications: WB, ICC/IF, IP, Flow Cyt

Antibody Name: Recombinant Anti-GFPT2 antibody [EPR19095]

Description: This recombinant targets GFPT2

Target Organism: rat, mouse, human

Clone ID: EPR19095

Antibody ID: AB_2868470

Vendor: Abcam

Catalog Number: ab190966

Record Creation Time: 20250820T031339+0000

Record Last Update: 20250820T154108+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-GFPT2 antibody [EPR19095].

No alerts have been found for Recombinant Anti-GFPT2 antibody [EPR19095].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Su H, et al. (2025) Targeting PGM3 abolishes SREBP-1 activation-hexosamine synthesis feedback regulation to effectively suppress brain tumor growth. Science advances, 11(16), eadq0334.

Xia W, et al. (2024) p53 promotes antiviral innate immunity by driving hexosamine metabolism. Cell reports, 43(2), 113724.

Ishikita A, et al. (2021) GFAT2 mediates cardiac hypertrophy through HBP-O-GlcNAcylation-Akt pathway. iScience, 24(12), 103517.